Viread (Tenofovir)
| Brand Name: |
Viread |
| Generic Name: |
Tenofovir disoproxil fumarate, TDF |
| Adult Single Dose: |
One 300-mg tablet (once a day) |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
NRTI |
The Basics
- Viread (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- An Overview of Viread (Tenofovir) (January 30, 2012)
From AIDSinfo
- Tenofovir (Viread) (January 21, 2012)
To read PDF, click here.
From AIDS InfoNet
- Patient Information About Viread (Tenofovir) (PDF) (January 2012)
From Gilead Sciences, Inc.
- Viread (Tenofovir) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Tenofovir (Viread) (August 15, 2006)
From AIDS Treatment Data Network
- Viread (Tenofovir) (November 2005)
[Archived Article]
To read PDF, click here.
From The Center for AIDS
- Drug Interactions: Tenofovir (August 2004)
[Archived Article]
From Project Inform
- Gilead's Viread International Access Program (May 2003)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Tenofovir: New Kind of Anti-HIV Drug Gets Approved (March 2002)
[Archived Article]
In Project Inform Perspective, from Project Inform
- Tenofovir DF 300 mg Consistently Demonstrates Anti-HIV Activity Regardless of Baseline Demographic Characteristics in Antiretroviral Experienced HIV-1-Infected Patients (October 29, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from TheBodyPRO.com
- FDA Briefing Documents on Tenofovir (October 3, 2001)
[Archived Article]
From U.S. Food and Drug Administration
- Position Paper on NDA 21-356 for Gilead Sciences' Viread Brand Tenofovir Disoproxil Fumarate (October 3, 2001)
[Archived Article]
In TAGline, from Treatment Action Group
- New Drugs in Development: Very Viread (Fall 2001)
[Archived Article]
A look at the drug's indications, resistance profile and some clinical trial results.
To read PDF, click here.
In CRIA Update, from AIDS Community Research Initiative of America
News
 Tenofovir Linked With Risk of Kidney Damage (February 21, 2012)
In Positively Aware, from Test Positive Aware Network
- Tenofovir Label Extended to Pediatric Indication (January/February 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Viread: New Formulation and Pediatric Dosing Update (January 19, 2012)
From U.S. Food and Drug Administration
- Scientists "Tinker" With HIV Drug Chemistry Hoping to Reduce Costs (May 13, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Expanded Indication for Viread, to Include the Treatment of Patients 12 to Less Than 18 Years of Age (March 24, 2010)
From U.S. Food and Drug Administration
- FDA Approves Gilead's Antiretroviral Viread for Use as Hepatitis B Treatment (August 13, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Gilead Sciences May Lose Patent for Viread (January 25, 2008)
Looser patent laws could mean generic version of Tenofovir to come.
In Housing Works AIDS Issues Update, from Housing Works
- U.S. Patent Agency to Review Gilead's Claim on Tenofovir (July 20, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Gilead Lowers Its No-Profit Drug Prices for Truvada, Viread (August 30, 2005)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Viread (Tenofovir Disoproxil Fumarate) Labeling Revision (May 13, 2005)
[Archived Article]
Among the revisions is updated information regarding drug resistance and long-term effects on bone mineral density.
From U.S. Food and Drug Administration
- Warning on Two Specific 3-Drug Regimens: Viread + Videx + Either Sustiva or Viramune (November 23, 2004)
[Archived Article]
A brief comment on the recently issued warning that both regimens frequently fail.
In AIDS Treatment News, from AIDS Treatment News
- Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration
- Food and Drug Administration to Expedite Decision on Emtricitabine/Tenofovir Pill (May 18, 2004)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Drug Development News: Fixed-Dose Combinations (May/June 2004)
The Food and Drug Administration's fast-track approval process for fixed-dose combinations is about to bear fruit.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Gilead Sciences First-Quarter Profits Driven by Increase in Sales of Antiretroviral Viread (April 26, 2004)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Atazanavir (Reyataz): New Recommendations if Combined With Tenofovir (Viread) -- and Warning on Viagra, Cialis, and Levitra (March 26, 2004)
[Archived Article]
New warnings on drug-drug interactions are noted in the prescribing information for atazanavir.
In AIDS Treatment News, from AIDS Treatment News
- Revised Labeling for Viread (Tenofovir Disoproxil Fumarate) 300 mg Tablets (November 4, 2003)
[Archived Article]
From U.S. Food and Drug Administration
- Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
[Archived Article]
To read PDF, click here.
From U.S. Food and Drug Administration
- FDA Orders Gilead for Second Time to Stop Downplaying Risks, Inflating Benefits of Antiretroviral Drug Viread (August 8, 2003)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Atazanavir/Tenofovir Combo Should Be Boosted With Ritonavir (August 8, 2003)
[Archived Article]
From U.S. Food and Drug Administration
- U.S. Approves Emtriva; Gilead Hopes Viread/Emtriva Combo Will Compete With Combivir (July 3, 2003)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- European Union Gives Thumbs-Up to Tenofovir Use in Treatment-Naive Patients (May 28, 2003)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- HIV-Positive Man Dies of Kidney Failure and Lactic Acidosis Due to Tenofovir/ddI Interaction (April 8, 2003)
[Archived Article]
From aidsmap.com
- Three French Cases of Tenofovir Kidney Toxicity Reported Amongst HIV-Positive Patients (April 8, 2003)
[Archived Article]
From aidsmap.com
- Gilead Offers Tenofovir to Developing Countries at Cost (April 4, 2003)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- New Safety Information -- Viread Co-Administration With Videx (September 30, 2002)
[Archived Article]
From U.S. Food and Drug Administration
- ddI-Tenofovir Interaction Warning (PDF) (May 7, 2002)
[Archived Article]
From Bristol-Myers Squibb Company
- More Uses for Tenofovir? (January 25, 2002)
[Archived Article]
The drug's usefulness in pregnant women, as a microbicide or as first-line therapy has yet to be thoroughly investigated.
To read PDF, click here.
In AIDS Treatment News, from AIDS Treatment News
- Nutrient Deficiency Associated With New HIV Medication (December 2001)
[Archived Article]
In Survival News, from AIDS Survival Project
- Tenofovir (Viread), First Novel Antiviral Agent in Six Years, Approved by FDA (November 2001)
[Archived Article]
In TAGline, from Treatment Action Group
- FDA Approves Viread for HIV-1 Infection (October 29, 2001)
[Archived Article]
From U.S. Food and Drug Administration
- Tenofovir Approved: Broad Indication (October 26, 2001)
[Archived Article]
To read PDF, click here.
In AIDS Treatment News, from AIDS Treatment News
- Tenofovir: FDA Hearing on Important New Antiretroviral (October 19, 2001)
[Archived Article]
To read PDF, click here.
In AIDS Treatment News, from AIDS Treatment News
- Expanded Access to Tenofovir (October 9, 2001)
[Archived Article]
From Canadian AIDS Treatment Information Exchange
- Activists Call for Immediate Approval of Viread Tenofovir DF (October 3, 2001)
[Archived Article]
In TAGline, from Treatment Action Group
- Tenofovir: FDA Hearing October 3, Public Comment Deadlines September 26 (August 24, 2001)
[Archived Article]
To read PDF, click here.
In AIDS Treatment News, from AIDS Treatment News
- Tenofovir DF on the Horizon (August/September 2001)
[Archived Article]
In Positive Living, from AIDS Project Los Angeles
- Tenofovir: Gilead Applies for Approval; Expanded Access Liberalized (May 11, 2001)
[Archived Article]
To read PDF, click here.
In AIDS Treatment News, from AIDS Treatment News
- Gilead Provides Expanded Access Program for Tenofovir (March 2001)
[Archived Article]
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- Tenofovir Expanded Access (Spring 2001)
[Archived Article]
To read PDF, click here.
In CRIA Update, from AIDS Community Research Initiative of America
- Tenofovir DF Expanded Access (February 23, 2001)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- Early Access Program Opened for Nucleotide Analogue Tenofovir (February 22, 2001)
[Archived Article]
In STEP Ezine, from Seattle Treatment Education Project
- PMPA (Tenofovir) -- Access Programs in Development (December 1999)
[Archived Article]
In Body Positive, from Body Positive
- Tenofovir Compassionate Use Program (September/October 1999)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
- PMPA in Perspective (December 1, 1995)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
|
|
Advertisement
|
Email
Glossary
